Health and Fitness Health and Fitness
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ] - Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011
Wed, February 16, 2011
Tue, February 15, 2011
Mon, February 14, 2011
Fri, February 11, 2011
Thu, February 10, 2011
Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011

NPS Pharmaceuticals to Present at Leerink Swann Hot Topics in Therapeutics Roundtable Conference


//health-fitness.news-articles.net/content/2011/ .. opics-in-therapeutics-roundtable-conference.html
Published in Health and Fitness on Friday, February 11th 2011 at 5:20 GMT by Market Wire   Print publication without navigation


BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference in New York on Thursday, February 17, 2011 at 2:20 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa™ calendar of events page on the NPS website at [ http://www.npsp.com/events ].

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is in Phase 3 development for parenteral nutrition dependent adult short bowel syndrome and is in preclinical development for additional intestinal failure related conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 3 development as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at [ http://www.npsp.com ].


Publication Contributing Sources